Compare CDZI & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | CDZI | LXEO |
|---|---|---|
| Founded | 1983 | 2017 |
| Country | United States | United States |
| Employees | 31 | 59 |
| Industry | Water Supply | |
| Sector | Utilities | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 413.8M | 369.8M |
| IPO Year | N/A | 2023 |
| Metric | CDZI | LXEO |
|---|---|---|
| Price | $4.16 | $5.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $18.44 |
| AVG Volume (30 Days) | ★ 768.4K | 714.3K |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $654,000.00 |
| Revenue This Year | $12.97 | N/A |
| Revenue Next Year | $102.40 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.66 | $2.51 |
| 52 Week High | $6.96 | $10.99 |
| Indicator | CDZI | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 37.79 | 40.87 |
| Support Level | $4.15 | $4.95 |
| Resistance Level | $5.10 | $5.11 |
| Average True Range (ATR) | 0.24 | 0.43 |
| MACD | -0.03 | -0.11 |
| Stochastic Oscillator | 20.30 | 31.83 |
Cadiz Inc is a water solutions provider, dedicated to delivering clean, reliable, and affordable water for people. It provides water solutions with a combination of land, water, pipeline, and water filtration assets located in Southern California between key water systems serving population centers in the Southwestern United States. The company operates in two reportable segments; Land and Water Resources segment, comprises all activities regarding its properties in the eastern Mojave Desert, pre-revenue development of the Mojave Groundwater Bank (supply, storage, and conveyance), and agricultural operations; and the Water Filtration Technology segment, generating maximum revenue engaged in providing water filtration solutions for impaired or contaminated groundwater sources.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.